Shares of Moderna surged 8.3% to $213.38 on October 9 as the biotech's addition to the Nasdaq-100 index took effect before the opening bell, forcing billions of dollars in index-tracking funds to buy the stock whether they wanted to or not.
Index Funds Had No Choice but to Buy Moderna Joins the Nasdaq-100 and Jumps 8% on Forced Buying — But Can a Stock This Far Above Analyst Targets Hold Its Gains?
Shares of Moderna vaulted 8.3% to $213.38 on October 9 as the company officially entered the Nasdaq-100, triggering a wave of mandatory purchases by funds that mechanically track the index. Nasdaq announced on October 1 that Moderna would join the benchmark, replacing Warner Bros. Discovery , and funds tracking the Nasdaq-100 needed to add Moderna by the opening bell on October 9. The question now: does this technical event mark a lasting floor, or a short-lived sugar rush for a stock trading far above Wall Street's fundamental view?
Over $800 Billion in Index Money Had to Make Room
The Nasdaq-100 is tracked by more than 200 investment products holding over $800 billion in assets under management. When a stock is added, every fund mirroring the index must buy shares regardless of price — that's "passive demand," purchasing driven by portfolio rules, not conviction. This kind of inclusion typically triggers passive index-fund buying and can boost liquidity. The result was visible: Moderna jumped $16.38 from Thursday's close of $197.00 in a single session.
The Stock Has Left Analysts Behind
The consensus from 23 analysts is Hold, with an average price target of just $119.56 — roughly $94 below today's price. More pointedly, Citigroup on September 30 downgraded Moderna to Sell with an $80 target , arguing it could not "justify the valuation" and that Moderna's roughly $80 billion market cap "approximates Regeneron's despite materially lower expected revenue." The stock is now trading at a price-to-sales ratio north of 33× — dramatically above its historical median of 8.4×, underscoring how much future growth the market is pricing in.
Fundamentals Haven't Changed Overnight
In Q2 2026, Moderna generated just $145 million in revenue and posted a $782 million net loss.
The index change gives Moderna a market-structure catalyst but does not alter the company's revenue or earnings profile. On the product side, the FDA approved its first mRNA flu vaccine on August 5 for adults 50 and older , and the stock has surged more than sixfold in 2026 , largely on excitement about a personalized cancer vaccine in late-stage trials.
The Risk Is What Happens After the Buying Stops Index inclusion is a one-time mechanical event. Any buying by passive funds can push up prices today — "transitory price pressure" — and therefore potentially lead to lower returns afterward. With every major analyst target far below the current price and profitability still distant, shareholders are betting that Moderna's pipeline can eventually grow into a valuation that, today, only the index machines were forced to pay.